Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Solvay Pharmaceuticals |
---|---|
Information provided by: | Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00126022 |
The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.
Condition | Intervention | Phase |
---|---|---|
Atrial Fibrillation Atrial Flutter |
Drug: Tedisamil sesquifumarate |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Global Clinical Director Solvay | Solvay Pharmaceuticals |
Study ID Numbers: | S219.3.116, 2004-000460-27 |
Study First Received: | August 1, 2005 |
Last Updated: | March 28, 2006 |
ClinicalTrials.gov Identifier: | NCT00126022 History of Changes |
Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Canada: Health Canada; Czech Republic: State Institute for Drug Control; Germany: Federal Institute for Drugs and Medical Devices; Israel: Israeli Health Ministry Pharmaceutical Administration; Poland: Ministry of Health; Romania: State Institute for Drug Control; Russia: Pharmacological Committee, Ministry of Health; Serbia and Montenegro: Agency for Drugs and Medicinal Devices; Slovakia: State Institute for Drug Control; South Africa: Medicines Control Council; United Kingdom: Medicines and Healthcare Products Regulatory Agency; Ukraine: State Pharmacological Center - Ministry of Health; United States: Food and Drug Administration |
Atrial fibrillation atrial flutter anti-arrhythmic agents conversion to normal sinus rhythm |
Heart Diseases Cardiovascular Agents Anti-Arrhythmia Agents Atrial Fibrillation |
Atrial Flutter Tedisamil Arrhythmias, Cardiac |
Heart Diseases Cardiotonic Agents Physiological Effects of Drugs Cardiovascular Agents Protective Agents Atrial Flutter Pharmacologic Actions |
Tedisamil Pathologic Processes Therapeutic Uses Cardiovascular Diseases Atrial Fibrillation Anti-Arrhythmia Agents Arrhythmias, Cardiac |